CCF Risk Calculator Library

Predicts the probabilities of postoperative naming, verbal memory, and mood decline following temporal lobe resection in older adolescents and adults (≥16 years)

For Patients With a Normal Appearing Hippocampus (HC) on MRI

Predicts the 1-year risk of recurrent seizure after temporal lobe epilepsy (TLE) surgery.

For Children Eligible for Resective Epilepsy Surgeries that Include the Temporal Lobe

Predicts the probabilities of postoperative verbal and visual memory decline following temporal lobe resection in children (ages 6-16)

Psychosis

For Youth at High Risk

Predicts the conversion to psychosis for youth who are at high risk due to symptoms, genetic risk, and recent decline in functioning based on a variety of tests and psychometric dimensions.

Spine Surgery

For Patients Eligible for Cervical Spine Surgery

Predicts probability of emergency department visit within 30 days, readmission within 30 days and reoperation for infection within 90 days. Predicts change in EQ-5D, PHQ-9 and PDQ quality-of-life metrics.

Bladder

For Patients Immediately Following Radical Cystectomy

Predicts 5-year progression-free probability.

Brain

For Patients Diagnosed with Brain Metastasis

Predicts 6-month, 12-month and median survival.

For Patients with Newly Diagnosed Glioblastoma

Predicts 6-, 12- and 24-month survival probability.

Breast

For Women with Breast Cancer Who Do Not Receive Adjuvant Therapy

Predicts 15-year risk of breast cancer specific death.

For Women with Positive Sentinel Node Biopsy

Predicts risk of additional node metastasis following complete axillary lymph node dissection.

For Women Considering or Undergoing Axillary Lymph Node Dissection

Predicts 5-year risk of arm lymphedema.

For Women Considering or Undergoing Mastectomy with N1 Breast Cancer

Predicts risk of recurrence and mortality.

Colorectal

For Patients After Liver Resection For Stage IV Colorectal Cancer

Predicts 96-month disease-specific survival.

For Patients Immediately Following Surgery

Predicts the 5- and 10-year recurrence-free survival percentage.

For Patients Without History of Colorectal Cancer, Inflammatory Bowel Disease, Familial Adenomatous Polyposis, Lynch Syndrome, or Adenomatous Polyps

Predicts 10-year colorectal cancer risk.

Gastric

For Patients Considering R0 Resection for Gastric Carcinoma

Predicts 5- and 9-year disease-specific survival.

For Pre-treatment Gastric Patients

Predicts 1-, 3-, and 5-year overall survival and disease-specific mortality.

Kidney

For Patients Immediately Following Partial or Radical Nephrectomy

Predicts 5- and 7-year freedom from recurrence and 7-year renal insufficiency.

For Patients With Metastatic Renal Cell Carcinoma

Predicts 12-month progression-free survival with sunitinib or pazopanib.

For Patients with Small Renal Masses

Predicts the probability of malignant pathology for small renal masses.

Melanoma

For Patients Immediately Prior to Sentinel Lymph Nodes Biopsy

Predicts the probability of positive sentinel nodes.

For patients with small choroidal melanocytic lesions

Predicts probability of small choroidal melanoma.

For Patients with Iris Melanocytic Tumors

Predicts probability of iris melanoma.

Oral

For Patients after Surgery Oral Cavity Squamous Cell Carcinoma

Predicts 5-year percentage of recurrence-free survival to assist in determining the need for adjuvant treatment.

Ovarian

For Patients after Primary Surgery for Bulky Stage IIIC Carcinoma

Predicts 5-year probability of survival.

Pancreatic

For Patients after Resection for Adenocarcinoma of the Pancreas

Predicts 12-, 24- and 36-month survival.

Penile

For Patients Having Undergone Surgery for Squamous Cell Carcinoma of the Penis

Predict 5-year cancer specific survival and lymph node involvement.

Prostate Cancer 1: Risk Prior to Diagnosis

For Patients Prior to Initial Biopsy

Predicts percentage chance of having prostate cancer and of having high grade prostate cancer to help determine treatment options.

For Patients with a Prior Negative 6- to 12-Core Biopsy in the past 6 months

Determines 4-year probability of outcomes with or without dutasteride.

For Patients with Prior Negative Biopsy

Predicts percentage of having prostate cancer with repeated prostate biopsy.

Prostate Cancer Prevention Trial Biopsy Risk Calculator (Deprecated, use PBCG below)

For patients who are undergoing prostate cancer screening with PSA and DRE.

Prostate Biopsy Collaborative Group Biopsy Risk Calculator

For patients who are undergoing prostate cancer screening with PSA and DRE.

Extended Prostate Biopsy Collaborative Group Biopsy Risk Calculator

For patients who are undergoing prostate cancer screening with PSA and DRE.

Prostate Cancer 2: Pre-Treatment

For Patients Immediately Prior to Surgery

Predicts the probability of upgrading the Gleason score in patients with low- and intermediate-grade prostate cancer on biopsy to help identify patients who may benefit from more aggressive or novel therapy.

For Patients Recently Diagnosed with Clinically Localized Prostate Cancer

Predicts 5- and 10-year probabilities for radical prostatectomy, watchful waiting, and 3-dimensional conformal radiation therapy of survival, indolent cancer, freedom from recurrence, metastasis and trifecta.

Prostate Cancer 3: Post-Treatment

For Patients Immediately Following Radical Prostatectomy

Predicts 7-, 9- and 10-year post-treatment freedom from recurrence, and 10- and 15-year cancer-specific mortality.

For Patients Immediately Following Brachytherapy

Predicts 7- and 9-year post-treatment freedom from recurrence.

Prostate Cancer 4: PSA Recurrence Following Radical Prostatectomy

For Patients with Biochemical Recurrence Following Radical Prostatectomy

Predicts the probability of freedom from biochemical failure at 5- and 10-year and cumulative incidence of metastasis at 5- and 10-year for men receiving salvage radiation therapy.